GB 264
Alternative Names: Claudin 18.2/CD3 bispecific antibody - Antibody Therapeutics; Claudin 18.2/CD3 BsAb - Antibody Therapeutics; Claudin 18.2xCD3 bispecific antibody - Genor Biopharma; GB-264Latest Information Update: 21 Jun 2021
At a glance
- Originator Genor Biopharma
- Developer Antibody Studio; Antibody Therapeutics; Genor Biopharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastrointestinal cancer; Pancreatic cancer
Most Recent Events
- 10 Apr 2021 Preclinical trials in Pancreatic cancer in China (Parenteral) (Genor Biopharma website, March 2021)
- 10 Apr 2021 Preclinical trials in Pancreatic cancer in USA (Parenteral)
- 10 Apr 2021 Pharmacodynamics data from a preclinical study in Pancreatic cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)